

## Australian Federal Government Announces Funding of SMART CRC

**Melbourne, Australia; 24 April 2025:** Australian Federal Government Minister for Industry and Science Hon Ed Husic MP has today announced the funding of the Solutions for Manufacturing Advanced Regenerative Therapies Cooperative Research Centre (the “**SMART CRC**”). Cynata (ASX: “**CYP**”, “**Cynata**”, or the “**Company**”) was a participant in the funding bid and intends to act as a Core Partner in the SMART CRC, subject to agreement on project plans and execution of formal agreements.

### Key Highlights

- The SMART CRC will be a national coordinated effort that harnesses Australia’s strengths across the entire value chain with a total budget of \$238M and over 60 partners spanning industry, government, healthcare, universities, and research institutes.
- The partners will develop and grow a cohesive and collaborative regenerative therapy manufacturing ecosystem in Australia through the SMART CRC, transforming Australia’s regenerative therapies sector into a mature, self-sufficient, collaborative, and sustainable manufacturing product and talent pipeline.
- The CRC partners will now move to draft and execute formal agreements.

### Prof Simon Cool, Interim Chief Executive Officer of the SMART CRC, said:

*“I am delighted about the positive funding decision. The total CRC budget of \$238m over ten years is very significant. The impressive cross-sector mobilisation of Australian thought leaders and stakeholders in manufacturing solutions for advanced regenerative therapies will allow partners such as Cynata Therapeutics to supercharge their innovative projects while at the same time spawning innovation in the entire ecosystem.”*

### Dr Kilian Kelly, Cynata’s Chief Executive Officer and Managing Director, said:

*“The SMART CRC brings together many of the best skills and capabilities in Australia and offers Cynata an attractive opportunity to translate some of its research and development plans into collaboration projects under the SMART CRC, enrolling top talent and using leveraged funding. We look forward to being part of the next steps to finalise the setup of the CRC.”*

**-ENDS-**

**Authorised for release by Dr Kilian Kelly, CEO & Managing Director**

**CONTACTS:** Dr Kilian Kelly, CEO & MD, Cynata Therapeutics, +61 (03) 7067 6940, [kilian.kelly@cynata.com](mailto:kilian.kelly@cynata.com)  
Lauren Nowak, Media Contact, +61 (0)400 434 299, [lauren@littlebigdeal.au](mailto:lauren@littlebigdeal.au)

### About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata has demonstrated positive safety and efficacy data for its Cymerus™ product candidates CYP-001 and CYP-006TK, in Phase 1 clinical trials in steroid-resistant acute graft versus host disease (GvHD), and diabetic foot ulcers (DFU), respectively. Further clinical trials are now ongoing: a Phase 2 trial of CYP-001 in GvHD under a cleared US FDA IND; a Phase 1/2 trial of CYP-001 in patients undergoing kidney transplantation; and a Phase 3 trial of CYP-004 in osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus™ technology in preclinical models of numerous other diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

**Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, [Automatic Group](#).**